Lung Cancer Trial, Recruiting NCT07458425 Sponsor: University of Illinois at Chicago Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07458425
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 50 and 80 years old (inclusive) at the time of signing the consent form
  • People whose smoking history and age meet the screening guidelines set by the U.S. Preventive Services Task Force (USPSTF) for low-dose CT lung screening (confirm with trial site)
  • People who are current or former patients at UI Health or Mile Square FQHC, including primary care and substance use disorder clinics
  • People who have smoked at least 20 pack-years and either currently smoke or stopped smoking within the last 15 years (a "pack-year" means smoking one pack of cigarettes per day for one year)
  • People who are able to sign a written consent form and a privacy authorization form themselves — consent from another person on the participant's behalf is not allowed under this trial
  • Women who could become pregnant must not be currently pregnant or breastfeeding, and a pregnancy test will be required
  • People who are able to understand and follow the study procedures for the full duration of the trial

Who may not be able to join:

  • People who smoked for more than 20 pack-years but stopped smoking 15 or more years ago
  • People who are currently being investigated or referred for further testing because a doctor suspects they may have cancer (for example, referred to an oncologist or scheduled for a biopsy based on a suspicious scan)
  • People who have been diagnosed with a serious cancer (solid tumour or blood cancer) within the past 5 years, or who were diagnosed more than 5 years ago but never received treatment — note that people with a history of non-spreading basal cell carcinoma or squamous cell carcinoma of the skin are not excluded
  • People who received active treatment for a serious cancer (solid tumour or blood cancer) within the past 5 years — note that ongoing hormone therapy for cancer (such as for breast or prostate cancer) does not automatically exclude someone (confirm with trial site)
  • People who are unlikely to be able to follow the study procedures
  • People who are not currently registered patients at UI Health (UIH)
  • People who are currently pregnant (based on self-report)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ameen Salahudeen, MD, PhD, University of Illinois at Chicago

Phone: (312) 355-1625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
11 March 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient Reported Outcomes Measurement Information System (PROMIS) survey results before and following the return of results (ROR); Multidimensional Impact of Cancer Risk Assessment (MICRA) following return of results (ROR); Perceptions and health beliefs relating to lung cancer screening using the Lung Health Belief Scale (Lung-HBS) perceived risk and perceived benefits after the return of results (ROR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov